Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

People who were hospitalised with COVID-19 and continued to experience symptoms five months later, show limited further recovery one year after hospital discharge, according to the latest results of a major national study looking at the long-term health impacts of COVID-19 on hospitalised patients.

Long road going on and on in the distance with COVID-19 written on it

The latest findings of the PHOSP-COVID study, which involves several researchers from the University of Oxford, have been published on the medRxiv pre-print website.

The study confirmed earlier research that people who were less likely to make a full recovery from COVID-19 were female, obese, and required invasive mechanical ventilation (IMV) to support their breathing during their hospital stay.

The PHOSP-COVID study, led by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre (BRC), has been given urgent public health research status by the Department of Health and Social Care. Around 10,000 patients are expected to take part in the study, making it one of the largest comprehensive studies in the world to understand and improve the health of survivors after hospitalisation from COVID-19.

Oxford investigators have been prominent in this study, providing expertise in multi-organ imaging, mental health and lung disease. The study involves an important collaboration between the city's two NHS Trusts (Oxford University Hospitals NHS Foundation Trust and Oxford Health NHS Foundation Trust), the two NIHR Biomedical Research Centres (Oxford BRC and Oxford Health BRC), as well as the University of Oxford.

Professor Ling-Pei Ho (Oxford BRC Respiratory Theme investigator), Professor John Geddes (Director of the Oxford Health BRC) and Professor Stefan Neubauer (Oxford BRC Theme Lead for Imaging) are part of PHOSP-COVID's national consortium group.

Researchers from 53 institutions and 83 hospitals across the UK assessed 2,230 adults who had been hospitalised with COVID-19. All participants have completed a five-month assessment and so far, 807 people have also completed a 12-month assessment.

Recovery was measured using patient-reported data, physical performance and organ function tests. Participant blood samples at the five-month visit were analysed for around 300 substances linked to inflammation and immunity.
The researchers found that one year after hospital discharge, fewer than three in 10 patients on the study reported they felt fully recovered, largely unchanged from 2.5 in 10 at five months. The most common ongoing symptoms were fatigue, muscle pain, physically slowing down, poor sleep and breathlessness.

Participants felt their health-related quality of life remained substantially worse one year after hospital discharge, compared to pre-COVID. This suggests the physical and mental health impairments reported in the study are unlikely to be pre-existing conditions.

Professor John Geddes, Department of Psychiatry, University of Oxford and Director of the NIHR Oxford Health BRC, said:

'The PHOSP-COVID study is a major achievement, pooling data and expertise from across the country to better understand the lasting physical and mental impacts of COVID-19 on hospitalised patients. These findings show that many people who developed long-COVID after being hospitalised have still not recovered a year after being discharged.

'More than half a million people have been admitted to hospital with COVID-19 in the UK, so as a country, we are looking at a significant proportion of the population at risk of persistent ill-health and reduced quality of life.'

Professor Ling-Pei Ho, said:

'PHOSP-COVID research teams have identified some differences in the blood samples of patients who are still experiencing the long-term physical and cognitive effects of their COVID-19 hospital admission. These might indicate possible underlying mechanisms, and help us identify existing medicines that target these mechanisms to help patients.

'Oxford has been a key contributor to this research, and it has been a massive team effort from the Long-COVID Clinic, BRC Integrative Respiratory Physiology Clinic, Oxford Respiratory Trials Unit, and research laboratories in Human Immunology Unit and Respiratory. Every patient who gave their time has contributed to this huge landmark study, which will continue to inform how we treat and support our post-COVID patients going forward.'

The PHOSP-COVID study, funded by the National Institute for Health Research, is also funded by the MRC-UK Research and Innovation (UKRI).

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.

Similar stories

How Mindfulness May Improve Body Satisfaction and Mood

New research from Emma Osborne, Research Assistant at the Centre for Research on Eating Disorders (CREDO) at the University of Oxford (and PhD Candidate at the University of Bath), and Dr Melissa Atkinson, University of Bath, investigated two ways in which mindfulness might improve body satisfaction and mood.

Review Highlights Risk Factors Associated with Violence in Schizophrenia

Researchers at Oxford University’s Department of Psychiatry have found that people with schizophrenia and related disorders are at higher-than-average risk of perpetrating violence, but that the overall risk remains low (less than 1 in 20 in women, and less than 1 in 4 for men over a 35-year period for violent arrests and crimes).

New Study will Investigate Brain Fog Symptoms in Post-Hospitalised COVID-19 Patients

C-Fog is a collaborative new study led by Oxford University researcher, Dr Maxime Taquet, which will investigate the reasons why brain fog or cognition problems affect patients after COVID-19 infection. With a better understanding of the mechanisms involved it may be possible to understand how to treat brain fog and help many thousands of people worldwide.

A New Experimental Study Investigated the Effects of Atorvastatin on Emotional Processing

Atorvastatin is one of a group of statins widely used to treat heart and blood vessel diseases. The medication works by lowering cholesterol in the blood. This new study shows that atorvastatin influences the way people experience certain emotions, giving us important insights about disorders such as anxiety and depression.

The Effects of Social Media on Public Attention and Attitudes Towards COVID-19 Vaccines in the UK

A new study finds that media coverage of positive vaccine research can have a positive effect on overall social media sentiment, countering vaccine misinformation, but the effects wane over time.

Should Children be Offered Vaccination against COVID-19?

New Rapid Ethics Review from the UK Pandemic Ethics Accelerator investigates the question of whether or not children should be offered vaccination against COVID-19, a question which has raised significant ethical challenges.